The
Philippines is not prepared to detect and
prevent the complications, including resistance to treatment, posed by the
tandem of tuberculosis (TB) and diabetes mellitus (DM).
Researchers of state
think-tank Philippine Institute for Development Studies (PIDS), led by Dr.
Emmanuel S. Baja, urge national health agencies to work together to initiate
research studies and produce a coordinated response to detect, prevent, and
manage the deadly TB-DM tandem in a study released by PIDS. The output of
Baja’s study is part of the Health System Research Management Project of the
PIDS and the Department of Health (DOH).
The International Diabetes
Foundation stated in their 2014 report that people with diabetes are prone to
contracting tuberculosis. In countries where there is a rising rate of diabetes,
there is an alarming and significantly matching spike in tuberculosis. The
compounded infection makes it hard for patients with both TB and DM to respond
to treatment.
The World Health Organization
in 2011 reported that TB patients who are diagnosed with diabetes have a higher
mortality risk.
At present, the Philippines
is ranked 15 as an emerging diabetes hotspot. At the same time, the country also has one of the highest
notified cases of multidrug resistant TB.
To understand the current
state of health programs to address the TB-DM tandem, the PIDS research team
surveyed the level of awareness and vigilance among medical practitioners to
test TB patients for DM and vice versa.
Majority of surveyed
physicians could adequately identify observable symptoms, and correctly
answered questions about diagnostic tests for either disease. However, less
than half appeared confident about the prevalence and risks of contracting both
disease.
More than two thirds do agree
that screening for TB in DM patients and DM in TB patients should be performed.
About a half of them agree that a TB-DM tandem presents difficulties in
treatment.
Focus group discussions with
the staff of the National TB Control Program (NTBCP) and the
Degenerative Diseases Office (DDO) of the DOH were conducted to determine the
current level of coordinated action to control and prevent the TB-DM tandem, as
well as evaluate the costs of bidirectional screening.
The study found the lack of
consensus among the staff of these agencies on how to address the TB-DM,
despite the 2011 WHO recommendation for countries with high rates of either
disease to pay attention to the “double burden of disease and the need for
joint surveillance, coordinated referral and management systems, a joint
research agenda”.
The study also revealed that
the DDO staff believed that screening for TB-DM is important and challenging,
but they didn’t necessarily view the tandem as a public health issue.
However, the NTBCP disagreed
that prevalence of DM in TB patients is an extensive problem, and underlined
the concerns that TB diagnosis might stigmatize DM patients.
The study recommends a pilot
study on the tandem disease. The current lack of initiative to detect it could
be related to the lack of information to guide the change in detection
policies.
The costly implementation of bidirectional screening, especially
screening TB in DM patients, also compounds the issue.
The PIDS-DOH study
strengthens the argument for a more informed study on the issue. It states, “Given
the government’s commitment to the nationwide control of TB, the underexplored
frontier of TB among diabetic patients can be among the stretch goals towards
increased case detection, management and prevention efforts.”
The national agencies
overseeing the care and control of TB and DM need to cooperate to increase
awareness among health workers and the general public about the prevalence and
risks of the tandem disease. They have to
coordinate their respective policies, programs, and operations, including
bidirectional screening, to detect and manage it. (PIDS)
Comments
Post a Comment